GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulse Biosciences Inc (NAS:PLSE) » Definitions » Valuation Rank

Pulse Biosciences (Pulse Biosciences) Valuation Rank


View and export this data going back to 2016. Start your Free Trial

What is Pulse Biosciences Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


Pulse Biosciences Valuation Rank Related Terms

Thank you for viewing the detailed overview of Pulse Biosciences's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Pulse Biosciences (Pulse Biosciences) Business Description

Traded in Other Exchanges
Address
3957 Point Eden Way, Hayward, CA, USA, 94545
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.
Executives
Robert W Duggan director, 10 percent owner 611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756
Kevin Patrick Danahy officer: Chief Commercial Officer 50 TEABERRY LANE, BRAINTREE MA 02184
Mitchell E. Levinson director 3957 POINT EDEN WAY, HAYWARD CA 94545
Manmeet Singh Soni director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Van Den Broek Richard director 73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Maky Zanganeh director 51 ADAM WAY, ATHERTON CA 94027
Sandra A. Gardiner officer: CFO & EVP Admin. and Finance CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Shelley D Spray director C/O PULSE BIOSCIENCES, INC., 3957 POINT EDEN WAY, HAYWARD CA 94545
Laureen Debuono director
Ed Ebbers officer: EVP & GM, Dermatology 3957 POINT EDEN WAY, HAYWARD CA 94545
Kenneth A Clark director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Fogarty Thomas J M D director C/O VENTURE LAW GROUP, 2800 SAND HILL RD STE 270, MENLO PARK CA 94025
Thierry B. Thaure director 3957 POINT EDEN WAY, HAYWARD CA 94545
Robert J. Greenberg director 12744 SAN FERNANDO ROAD, BLDG. 3, SYLMAR CA 91342
Brian B Dow officer: CFO & SVP Admin. and Finance 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588